Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50% / MedCity

Frank Vinluan / medcitynews - Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for pre…

#healthcare #publichealth #biotech #medicaldevices #oncology


Saturday, February 21, 2026, 12:23 am / permalink 19500 / 9 stories in 18 days



Related Stories




Related Tags



StackHealth Time Machine





NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.